Managing atherosclerosis in patients with type 2 diabetes mellitus and metabolic syndrome

American Journal of Therapeutics

Volumn 13, Issue 1, 2006, Pages 64-71

  Venkatapuram, Suneetha ^a   Shannon, Richard P ^a  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

Author keywords

Atherosclerosis; C reactive protein; Diabetes; Insulin resistance; Nitric oxide; Thiazolidinediones

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FENOFIBRATE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; NICOTINIC ACID; PIOGLITAZONE; ROSIGLITAZONE; THIAZIDE DIURETIC AGENT;

ATHEROSCLEROSIS; CLINICAL TRIAL; DIET THERAPY; DYSLIPIDEMIA; EXERCISE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; UNITED STATES;

ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; ATHEROSCLEROSIS; DIABETES MELLITUS, TYPE 2; DIET; EXERCISE; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; METABOLIC SYNDROME X; WEIGHT LOSS;

EID: 31544450026     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-200601000-00011     Document Type: Review

References (30)

1. Libby P. Changing concepts of atherogenesis. J Intern Med. 2000;247:349-358.
2. Creager MA, Luscher TF, Cosentino F, et al. Diabetes and vascular disease. Pathophysiology, clinical consequences, and medical therapy: part 1. Circulation. 2003;108:1527-1532.
3. Schmidt AM, Stern D. Atherosclerosis and diabetes: the RAGE connection. Curr Atheroscler Rep. 2000;2:430-436.
4. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis. Epidemiology, pathophysiology, and management. JAMA. 2002;287:2570-2581.
5. Reaven G. Metabolic syndrome. Pathophysiology and implications for management of cardiovascular disease. Circulation. 2002;106:286-288.
6. Garvey WT, Hermayer KL. Clinical implications of the insulin resistance syndrome. Clin Cornerstone. 1998;1:13-28.
7. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults. Findings from the Third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-359.
8. Stern MP. Perspectives in diabetes. Diabetes and cardiovascular disease. The "common soil." Hypothesis Diabetes. 1995;44:369-374.
9. Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996;334:952-957.
10. Girman CJ, Rhodes T, Mercuri M, et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS). Am J Cardiol. 2004;93:136-141.
11. Ridker PM. On evolutionary biology, inflammation, infection, and the causes of atherosclerosis. Circulation. 2002;105:2-4.
12. Festa A, D'Agostino R, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome. The Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102:42-47.
13. Scott CL. Diagnosis, prevention, and intervention for the metabolic syndrome. Am J Cardiol. 2003;92:35i-42i.
14. Fujimoto WY. The importance of insulin resistance in the pathogenesis of type 2 diabetes mellitus. Am J Med. 2000;108:9S-14S.
15. Gilling L, Suwattee P, DeSouza C, et al. Effects of the thiazolidinediones on cardiovascular risk factors. Am J Cardiovasc Drugs. 2002;2:149-156.
16. Chen Y, Fu M, Zhang J, et al. Peroxisome proliferator-activated receptors and the cardiovascular system. Vitam Horm. 2003;66:157-188.
17. Uwaifo GI, Ratner RE. The roles of insulin resistance, hyperinsulinemia, and thiazolidinediones in cardiovascular disease. Am J Med. 2003;115:12S-19S.
18. Creager MA, Luscher TL. Diabetes and vascular disease. Pathophysiology, clinical consequences, and medical therapy: part 2. Circulation. 2003;108:1655-1661.
19. Sobel BE. Insulin resistance and thrombosis: a cardiologist's view. Am J Med. 1999;84:37J-41J.
20. Stout RW. Hyperinsulinemia and atherosclerosis. Diabetes. 1996;45:S45-S46.
21. McLaughlin T, Abbasi F, Lamendola C, et al. Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation. 2002;106:2908-2912.
22. Skrha J. Pathogenesis of angiopathy in diabetes. Acta Diabetol. 2003;40(suppl 2):S324-S329.
23. McLaughlin T, Abbasi F, Cheal K, et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med. 2003;139:802-809.
24. McKenney JM. New cholesterol guidelines, new treatment challenges; Pharmacotherapy. 2002;22:853-863.
25. Sowers JR. Recommendations for special populations: diabetes mellitus and the metabolic syndrome. Am J Hypertens. 2003;16:41-45.
26. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes. JAMA. 2002;287:360-372.
27. Cottrell DA, Marshall BJ, Falko JM. Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome. Curr Opin Cardiol. 2003;18:301-308.
28. Kendall DM, Sobel BE, Coulston AM, et al. The insulin resistance syndrome and coronary artery disease. Coron Artery Dis. 2003;14:335-348.
29. Raji A, Plutzky J. Insulin resistance, diabetes, and atherosclerosis: thiazolidinediones as therapeutic interventions. Curr Cardiol Rep. 2002 Nov;4:514-521.
30. Grundy SM, Cleeman IJ, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education program. Adult Treatment Panel III Guidelines. Circulation. 2004;110:227-239.